Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 8.5% IN PLASTIC CONTAINER vs AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Protein calorie malnutrition,Catabolic states (e.g., burns, major surgery, trauma)
Total parenteral nutrition (TPN) for patients with inadequate oral/enteral intake,Peripheral parenteral nutrition when central line is not indicated
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
Intravenous infusion: 500 m L to 1000 m L per day, typically at a rate not exceeding 3 m L/kg/hour. Adjusted based on metabolic needs and fluid status.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
GFR 30-59 m L/min: reduce to 0.5-0.8 g protein/kg/day; GFR <30 m L/min: 0.4-0.5 g/kg/day; monitor BUN and electrolytes.
Contraindicated in severe renal impairment (GFR < 30 m L/min) or dialysis due to risk of volume overload and electrolyte abnormalities. For moderate impairment (GFR 30-59 m L/min), reduce dose by 50% and monitor electrolytes.
Not for use in patients with severe hepatic failure, severe uremia, or inborn errors of amino acid metabolism. Risk of hyperammonemia and metabolic acidosis.
Amino acid solutions like TRAVASOL 8.5% are essential for maternal nutrition in pregnancy; however, there are no well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use during pregnancy only if clearly needed. First trimester: potential risks are not established; avoid unless maternal benefit outweighs unknown fetal risk. Second and third trimesters: may be used cautiously for nutritional support, with monitoring for electrolyte imbalances and fluid overload in the fetus.
No teratogenic risk data specific to this combination. Both components are essential nutrients; dextrose and amino acids are not teratogenic at standard doses. However, hyperglycemia from dextrose may be associated with congenital anomalies if glucose levels are poorly controlled. No trimester-specific risks identified.
TRAVASOL 8.5% is a crystalline amino acid solution used for parenteral nutrition. It contains 8.5% amino acids and provides 85 g protein/L. It is hypertonic (approx. 880 m Osm/L) and must be administered via a central line to avoid thrombophlebitis. Shake container vigorously before use; do not use if cloudy or precipitate present. Do not add medications directly to the plastic container without checking compatibility. Protect from light; do not freeze. Use dedicated IV line without simultaneous blood products due to risk of agglomeration.
Monitor serum electrolytes, glucose, and renal function daily. Administer via central line due to high dextrose concentration (25%) to prevent thrombophlebitis. Use with caution in patients with renal impairment, heart failure, or hyperglycemia. Avoid rapid infusion to prevent osmotic diuresis. Check for allergies to corn products (dextrose source).
No interactions on record
No interactions on record
TRAVASOL 8.5% IN PLASTIC CONTAINER and AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER are distinct pharmacological agents. TRAVASOL 8.5% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Total parenteral nutrition in patients with inadequate oral or enteral intakeProtein calorie malnutritionCatabolic states (e.g., burns, major surgery, trauma). AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Total parenteral nutrition (TPN) for patients with inadequate oral/enteral intakePeripheral parenteral nutrition when central line is not indicated. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRAVASOL 8.5% IN PLASTIC CONTAINER carries a safety status of Category C, whereas AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via deamination, transamination, and oxidative pathways primarily in the liver. Nitrogen is incorporated into urea via the urea cycle.
Amino acids are metabolized primarily in the liver via transamination and deamination; dextrose undergoes glycolysis and subsequent oxidative metabolism.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Minimal (<10%) for individual amino acids; binding to albumin or other plasma proteins is negligible. Transport is primarily via specific carrier-mediated processes.
Amino acids: minimal (<10%), bound to albumin and globulins; dextrose: negligible binding.
Approximately 0.3–0.5 L/kg for total amino acids, reflecting distribution into total body water and intracellular compartments. Higher distribution for branched-chain amino acids (leucine, isoleucine, valine) into muscle.
Amino acids: Vd = 0.15-0.3 L/kg (total body water). Dextrose: Vd = 0.2 L/kg (extracellular fluid). Clinical meaning: distributes primarily into lean body mass and extracellular spaces.
Intravenous: 100% (complete). Not administered orally; if taken orally, amino acids are absorbed with bioavailability >90% but first-pass metabolism reduces systemic availability of some (e.g., glutamine, alanine).
Intravenous: 100%. Not administered via oral or other routes due to product formulation.
Child-Pugh Class A: no adjustment; Class B: reduce to 0.6-0.8 g protein/kg/day; Class C: 0.4-0.6 g/kg/day; avoid in hepatic encephalopathy.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50% and monitor ammonia levels. Class C: Avoid use due to risk of hepatic encephalopathy.
Weight-based: 1.0-2.5 g protein/kg/day intravenously, adjusted for age and clinical status; neonates: 1.5-3.0 g/kg/day.
Weight-based: 2-3 g amino acids/kg/day and 10-15 g dextrose/kg/day. Infuse at rate of 0.1-0.2 g dextrose/kg/hour initially, titrate to maintain blood glucose between 80-120 mg/d L.
Start at lower end of adult range (0.8-1.0 g/kg/day) and titrate based on renal function and metabolic tolerance; monitor fluid and electrolyte balance closely.
Reduce initial rate to 1-2 m L/kg/hour, monitor fluid balance closely due to increased risk of hypervolemia and renal impairment. Adjust based on GFR and cardiac function.
Death may occur due to improper administration; must be used under medical supervision. Solutions are hypertonic and may cause severe complications if extravasation occurs.
There are no direct food interactions as this is an intravenous solution. However, oral food intake is usually restricted or absent during parenteral nutrition therapy. Monitor for refeeding syndrome in severely malnourished patients.
No direct food interactions, but enteral intake should be coordinated if transitioning to oral feeding. Avoid high-sugar foods if hyperglycemia occurs.
TRAVASOL 8.5% is a sterile, hypertonic amino acid solution for intravenous infusion. It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRAVASOL 8.5% is administered to a nursing woman. The molecular weight of amino acids (< 200 Da) suggests potential for transfer into breast milk, but clinical significance is low due to endogenous presence. M/P ratio: not established.
Both dextrose and amino acids are endogenous substances and are excreted into breast milk in small amounts. No M/P ratio available. Considered compatible with breastfeeding; use only if clearly needed and monitor infant for hyperglycemia.
No specific dose adjustments are recommended during pregnancy based on pharmacokinetic changes. However, pregnancy increases plasma volume and renal blood flow, potentially altering amino acid clearance. Dose should be individualized based on maternal nutritional status, clinical response, and laboratory monitoring. Avoid overhydration and hyperglycemia. Use with caution in preeclampsia or gestational diabetes.
No specific dosing adjustments recommended for pregnancy; however, increased fluid volume and renal clearance may necessitate monitoring of electrolyte and glucose levels. Glucose infusion rate should be adjusted to maintain euglycemia.
This medication is given through a vein to provide protein calories when you cannot eat normally.,Your healthcare provider will monitor your blood sugar, kidney, and liver function regularly.,Tell your doctor if you experience fever, chills, flushing, or injection site pain.,Do not stop or adjust the infusion rate without consulting your healthcare team.,If you have diabetes, your blood glucose may rise; follow your management plan.
This solution provides nutrition through a vein; report any swelling, pain, or redness at the infusion site.,You may need frequent blood tests to monitor your blood sugar, kidney function, and electrolyte levels.,Tell your healthcare provider if you have diabetes, kidney disease, or heart failure.,Do not stop the infusion abruptly; the rate will be adjusted gradually.